© 2020 MJH Life Sciences and Urology Times. All rights reserved.
Prostate Cancer
Cancer-related pain indicative of poor prognosis for metastatic CSPC
August 07, 2020
Investigators found that while patients without pain had an overall survival of 56 months, patients with pain had an overall survival of only 27 months.
Hydrogel spacer may reduce rectal irradiation in patients receiving RT for prostate cancer
July 30, 2020
Injection of an absorbable perirectal hydrogel spacer prior to radiotherapy for prostate cancer may reduce rectal irradiation and the associated rectal toxic effects that manifest clinically after longer-term follow-up.
Darolutamide efficacy sustained in nonmetastatic CRPC patients with rapid PSA doubling time
July 30, 2020
A subgroup analysis of the pivotal phase 3 ARAMIS trial showed that the efficacy of darolutamide was sustained in patients with a rapid PSA double time.
Men on active surveillance for prostate cancer may benefit from Mediterranean diet
July 28, 2020
Mediterranean diet score was modestly associated with time to grade group progression.
Are phase 3 HERO results a game-changer for urologists?
July 28, 2020
"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.
Study reveals risk factors for upgrading in active surveillance for prostate cancer
July 27, 2020
“Our findings suggest that genomic score and PSA density are risk factors for upgrading within 3 years of commencing active surveillance,” the investigators wrote.
Oral gonadotropin-releasing hormone receptor antagonist shows benefits
July 27, 2020
Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.
68Ga-PSMA-11 PET imaging triggers major changes in management of biochemically recurrent prostate cancer
July 23, 2020
Referring physicians implemented PSMA PET–based treatment changes in 72% of patients.
Dosing starts in SPOTLIGHT study of rhPSMA-7.3 (18F) PET in biochemically recurrent prostate cancer
July 22, 2020
The phase 3 SPOTLIGHT study is assessing the diagnostic capability of rhPSMA-7.3 (18F) PET in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy.
Few significant prostate cancers are undetected by mpMRI
July 22, 2020
Cancers that are missed by mpMRI are significantly smaller and less aggressive than those that are detected.